Some tailored target therapies for CTCL are chiefly based on the blockade/inhibition of certain receptors/proteins (IL-2R/CD25, CD4, CD30, and CD52), whose expression by cancer cells can be identified by techniques as immunohistochemistry [15, 16]. The gene discussed is IL2RA; the disease is cancer.